Repligen Co. (NASDAQ:RGEN) CEO Sells $6,721,018.20 in Stock

Share on StockTwits

Repligen Co. (NASDAQ:RGEN) CEO Anthony Hunt sold 45,351 shares of the firm’s stock in a transaction on Thursday, September 10th. The stock was sold at an average price of $148.20, for a total value of $6,721,018.20. Following the completion of the transaction, the chief executive officer now owns 278,678 shares in the company, valued at approximately $41,300,079.60. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of RGEN opened at $150.27 on Wednesday. The stock’s 50-day simple moving average is $148.33 and its 200 day simple moving average is $122.57. Repligen Co. has a 52-week low of $72.32 and a 52-week high of $159.97. The stock has a market capitalization of $7.89 billion, a price-to-earnings ratio of 259.09, a price-to-earnings-growth ratio of 4.04 and a beta of 1.12. The company has a debt-to-equity ratio of 0.22, a quick ratio of 13.90 and a current ratio of 15.48.

Repligen (NASDAQ:RGEN) last released its quarterly earnings results on Thursday, July 30th. The biotechnology company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.14. The firm had revenue of $87.46 million for the quarter, compared to analysts’ expectations of $78.11 million. Repligen had a return on equity of 5.93% and a net margin of 10.23%. On average, research analysts forecast that Repligen Co. will post 1.28 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of RGEN. Steward Partners Investment Advisory LLC raised its stake in shares of Repligen by 48.1% in the second quarter. Steward Partners Investment Advisory LLC now owns 200 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 65 shares during the last quarter. Blair William & Co. IL raised its stake in Repligen by 1.3% in the 2nd quarter. Blair William & Co. IL now owns 6,149 shares of the biotechnology company’s stock worth $760,000 after acquiring an additional 80 shares during the last quarter. Prospera Financial Services Inc grew its position in Repligen by 1.4% during the 2nd quarter. Prospera Financial Services Inc now owns 7,037 shares of the biotechnology company’s stock worth $870,000 after purchasing an additional 94 shares during the period. Mercer Global Advisors Inc. ADV grew its position in shares of Repligen by 3.7% during the 1st quarter. Mercer Global Advisors Inc. ADV now owns 2,748 shares of the biotechnology company’s stock valued at $265,000 after acquiring an additional 98 shares during the period. Finally, Flagship Harbor Advisors LLC grew its position in shares of Repligen by 39.9% during the 2nd quarter. Flagship Harbor Advisors LLC now owns 526 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 150 shares during the period. Institutional investors and hedge funds own 97.87% of the company’s stock.

Several analysts have recently weighed in on RGEN shares. Stifel Nicolaus boosted their price target on Repligen from $135.00 to $150.00 and gave the stock a “buy” rating in a report on Wednesday, May 27th. HC Wainwright upped their target price on Repligen from $151.00 to $168.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. Finally, BidaskClub downgraded Repligen from a “buy” rating to a “hold” rating in a report on Monday, August 17th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $139.50.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Recommended Story: What is a Real Estate Investment Trust (REIT)?

Insider Buying and Selling by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Castor Maritime  Stock Price Down 5.7%
Castor Maritime Stock Price Down 5.7%
G1 Therapeutics  Trading Down 6.2%
G1 Therapeutics Trading Down 6.2%
CytomX Therapeutics  Trading Down 6.2%
CytomX Therapeutics Trading Down 6.2%
BridgeBio Pharma  Trading Down 6%
BridgeBio Pharma Trading Down 6%
Kite Realty Group Trust  Trading Down 6%
Kite Realty Group Trust Trading Down 6%
Arch Capital Group  Stock Price Down 5.9%
Arch Capital Group Stock Price Down 5.9%


 
© 2006-2020 Zolmax.